Past studies have shown that epidermal growth factor (EGF) is able to mimic the uterotropic effects of estrogen in the rodent. These studies have suggested a "cross-talk" model in which EGF receptor (EGF-R) signaling results in activation of nuclear estrogen receptor (ER) and its target genes in an estrogen-independent manner. Furthermore, in vitro studies have indicated the requirement for ER in this mechanism. To verify the requirement for ER in an in vivo system, EGF effects were studied in the uteri of ER knockout (ERKO) mice, which lack functional ER. The EGF-R levels, autophosphorylation, and c-fos induction were observed at equivalent levels in both genotypes indicating that removal of ER did not disrupt the EGF responses. Induction of DNA synthesis and the progesterone receptor gene in the uterus were measured after EGF treatment of both ERKO and wild-type animals. Wild-type mice showed increases of 4.3-fold in DNA synthesis, as well as an increase in PR mRNA after EGF treatment. However, these responses were absent in ERKO mice, confirming that the estrogen-like effects of EGF in the mouse uterus do indeed require the ER. These data conclusively demonstrate the coupling of EGF and ER signaling pathways in the rodent reproductive tract.
Estradiol, epidermal growth factor (EGF), and insulin-like growth factors are known mitogens in the rodent reproductive tract (1) (2) (3) . Estrogen has been shown to increase the uterine levels of both EGF and its receptor (EGF-R) (3) (4) (5) (6) (7) (8) (9) (10) , suggesting a link between the mitogenic effects of estrogens and growth factors. Furthermore, EGF has been shown to mimic the effects of estrogen in the mouse reproductive tract in terms of increased DNA synthesis and cornification of the vaginal epithelium (11) , as well as increased phosphorylation and nuclear retention of the estrogen receptor (ER) (12) . When estradiol is administered in conjunction with an EGF-specific antibody, a 60-70% reduction in the hormone-induced proliferation of the epithelium is observed in the mouse uterus and vagina (11) . These data indicate a possible role for EGF as a mediator of estrogen action. Further evidence of EGF/ estrogen cross-talk was provided by experiments showing that pre-treatment of mice with the pure anti-estrogen ICI 164,384 greatly diminished the uterine response to EGF (12) . Because ICI 164,384 significantly reduces the level of uterine ER (13) , these studies suggest the necessity for the ER in the mitogenic actions of EGF. This was supported by studies in Ishikawa cells, a human endometrial carcinoma cell line devoid of ER, in which an estrogen-responsive chloramphenicol acetyltransferase reporter gene could only be activated by EGF after cotransfection with an ER-expression plasmid (14) .
These studies have led to a model in which EGF plays a role in ER-mediated events in a ligand-independent manner. To gain further insight into the role of the ER in this cross-talk mechanism, EGF studies were carried out in the ER "knockout" (ERKO) mice. In the ERKO, both alleles of the ER gene have been disrupted via homologous recombination, resulting in a female reproductive tract that is nonresponsive to estrogen as described (15, 16) . To address the concern that lack of ER might disrupt the expression and functioning of the EGF-R signaling pathway, EGF-R levels, its autophosphorylation, and the induction of c-fos, an EGF-regulated gene, were determined. Then ERKO animals, as well as wild-type controls, were treated with EGF, and induction of DNA synthesis and the progesterone receptor (PR) gene were measured to confirm whether ER is required for the estrogenic activities of EGF. (17) .
MATERIALS AND METHODS
Solubilized membranes were subjected to an in vitro autophosphorylation assay by incubation in the presence or absence of EGF (17) . After stopping the reaction, equivalent amounts of total protein (25 ,ug per lane) were separated by SDS/PAGE (8% acrylamide), transferred to Immobilon membrane (Millipore), and the tyrosine-phosphorylated proteins were immunodetected using a monoclonal anti-phosphotryrosine antibody (anti-PTyr 3300, Sigma) and enhanced chemiluminescence as described (17) . The position of the EGF-R band was determined based on the molecular weight markers as previously determined (17 RNase Protection Assay (RPA). RPAs were used to measure the relative amounts of c-fos mRNA in both wild-type and ERKO mice. The animals were ovariectomized 10-14 days prior to subcutaneous injection of 30 ,ug EGF (receptor grade, Collaborative Research) in PBS. Some animals were pretreated with 1 mg/kg of the estrogen antagonist ICI 182,780 in dimethyl sulfoxide (DMSO) 30 min prior to EGF treatment. Control animals were treated with DMSO and PBS. Thirty minutes after EGF treatment, animals were killed and total RNA was prepared from uteri using Trizol (Life Technologies, Gaithersburg, MD) according to the manufacturer's protocol. RPAs were carried out using the Ambion HybSpeed RPA kit (Ambion, Austin, TX), according to the manufacturer's protocol. All probes were prepared using the Ambion Maxiscript
In Vitro Transcription kit (Ambion) and labeled with [32p]_ CTP (Amersham). The probe for c-fos mRNA was generated from the pTRI-c-fos/exon 4-mouse template plasmid (Ambion) and protected a 250-nt fragment of exon 4 sequences of the mouse c-fos transcript. The probe for normalization was generated from the pTRI-cyclophilin-mouse template plasmid (Ambion) and protects a 103-nt fragment of the mouse cyclophilin transcript. Final RPA reactions were separated on a 5% bis-acrylamide/8.3 M urea/i x TBE gel (100 mM Tris-Borate/0.2 mM EDTA, pH 8.3) (National Diagnostics). Markers were generated from the Ambion Century Marker Template Set and labeled by incorporation of [32P]-CTP.
[3HIThymidine Incorporation Assay. EGF (mouse receptor grade) was obtained from Collaborative Research and made into pellets (5 ,tg per pellet) by Innovative Research of America. Animals were ovariectomized 10-14 days before treatment. Pellets were split into four sections, animals were anaesthetized, and one-quarter of an EGF or placebo pellet was inserted into the intraperitoneal cavity through a 13-gauge trochar needle. Animals were sacrificed 16-18 hr later, and the uterus was removed and divided into two portions. One uterine horn was frozen in liquid nitrogen for RNA preparation (see below), while the other was slit longitudinally to expose the luminal epithelium and used in the [3H]thymidine incorporation assay as described (13) .
Northern Blot Analysis. RNA prepared from the uterine horns from the EGF-or placebo-treated animals was analyzed by Northern blot analysis as described (16) . The PR probe was an 1100-bp cDNA fragment encoding the DNA and ligandbinding regions of the mouse PR (bp 1667-2781). Equivalent RNA loading was confirmed by probing with a portion of the ribosomal protein L-7 (PL-7) cDNA (bp 371-639) as described (16 To determine if the level of EGF-R in the ERKO was sufficient to elicit a gene response, RNA was prepared from uteri of animals 30 min after subcutaneous injection of EGF, and c-fos levels were determined by RPA (Fig. 2) . Levels of c-fos mRNA were induced 18-fold in the wild-type uterus and 13-fold in the ERKO, after normalizing to the level of cyclophilin mRNA. This response in both genotypes indicates that although the EGF-R level is lower in the ERKO (Table 1) , the EGF-R signaling pathway is intact and able to mediate gene activation in ERKO mice. Because c-fos is also known to be an estrogen inducible gene (18), we wanted to determine whether the EGF induction might have an ER-mediated component via 
RESULTS
Estrogen up-regulates the EGF-R in the mouse uterus (3) . Therefore, removal of the ER during development might alter the level of EGF-R, and it was necessary to determine the levels of EGF-R in the ERKO mouse before proceeding with the studies of EGF action. As shown in Table 1 , EGF-R was present in membranes from the uteri and liver of ERKO animals, although at a level 35% and 15% lower, respectively, than the wild-type levels. The EGF-R also undergoes autophosphorylation in both tissues in response to ligand (Fig. 1), indicating that the EGF-R can be activated by EGF in the ERKO mouse. Proc. Natl. Acad. Sci. USA 93 (1996) the proposed cross-talk mechanism. The antiestrogen ICI 182,780, however, did not diminish the induction of c-fos by EGF in wild-type animals, indicating that ER is not involved in EGF induction of c-fos at this early time point of 30 min. The increased EGF induction after ICI pre-treatment is most likely due to the DMSO vehicle, since DMSO pre-treatment caused a similar enhancement of EGF activity (data not shown), possibly due to increased EGF-R autophosphorylation following DMSO treatment (19) .
The ERKO uterus has previously been shown to lack a growth response following estradiol treatment as measured by a uterotropic bioassay and [3H]thymidine incorporation (15, 16) . To determine if EGF would initiate DNA synthesis in the ERKO uterus, ovariectomized ERKO and wild-type animals were implanted with EGF releasing pellets, and DNA synthesis measured using relative [3H]thymidine incorporation. After 16-18 hr of EGF treatment, wild-type uteri showed a 4.3-fold increase in [3H]thymidine incorporation over placebo-treated animals, whereas the ERKO mice showed no increase in DNA synthesis compared with the placebo control (Fig. 3) .
The PR gene is also estrogen regulated in the rodent uterus (20, 21) ; however, it is not induced by estrogen in the ERKO (16) . To determine whether PR mRNA could be induced by EGF, RNA was prepared from uterine tissue after in vivo treatments with EGF pellets with or without pre-treatment with the pure anti-estrogen ICI 182,780. Northern blot analysis (Fig. 4) revealed that PR message increases after EGF treatment in the wild-type animals, but not in the ERKO mice. In addition, the anti-estrogen ICI 182,780 is able to block the EGF induction of the PR in the wild type, and has no effect on the ERKO.
DISCUSSION
This study, in combination with our previous studies and those of others (11, 12, 14, 22) , have led us to propose a model of "cross-talk" or interaction between the EGF and estrogen signaling pathways such that EGF-R activation can result in activation of ER target genes in the absence of estrogen (Fig.  5 ). In this model, the EGF-R and ER pathways can initiate distinct and separable signals that modulate responses of their respective target genes. However, it is also possible to couple the two pathways when, as depicted by the cross-hatched arrow in Fig. 5 (22) . In this study we were able to show an EGF-induced increase in PR mRNA in vivo.
In addition, the mRNA induction required ER because EGF did not induce the PR in ERKO mice or in wild-type mice that had been treated with the anti-estrogen ICI 182,380.
The mechanism of this EGF-R-mediated ER activation is unknown, but in vitro studies using a truncated ER illustrated the importance of amino terminal sequences for activation by EGF (14) . The ER mediates transcriptional activities by using two transcription activation functions or AFs (2, (23) (24) (25) . AF-1 is a ligand-independent activation function in the N terminus and AF-2 is a ligand-dependent activation function in the ligand-binding domain. An ER deletion mutant lacking the hormone-binding domain was activated by EGF, whereas a deletion mutant lacking the AF-1 was not (14) . Phosphorylation in the AF-1 region of the ER is a likely mechanism of EGF-mediated activity, because EGF-R activation results in phosphorylation and consequent modulation of the activities of several cellular kinases (26) (27) (28) , and subsequent phosphorylation and activation of nuclear transcription factors (26) (27) (28) (36) . Membrane permeable agents that increase cellular phosphorylation, such as 8-bromo-cAMP and okadaic acid, also enhance progesterone-dependent gene transcription (37) . Dopamine, a neurotransmitter, has been shown to induce ligand-independent activation of several nuclear receptors including the chicken PR (38, 39) and the human ER (40) . Together with the activation of mouse ER by EGF, these results confirm the existence of conserved cross-talk mechanisms between membrane receptors and nuclear receptors.
